H. Adam

发表

Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11.

M. Mulvey, J. Blondeau, D. Low, 2013, The Journal of antimicrobial chemotherapy.

Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals.

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2013, The Journal of antimicrobial chemotherapy.

Antimicrobial Resistance in Urinary Tract Pathogens in Canada from 2007 to 2009: CANWARD Surveillance Study

Patricia J. Simner, J. Karlowsky, D. Hoban, 2011, Antimicrobial Agents and Chemotherapy.

Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2016, Drugs.

Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin

J. Karlowsky, D. Hoban, H. Adam, 2012, Expert review of anti-infective therapy.

Subspecies-specific sequence detection for differentiation of Mycobacterium abscessus complex

J. Dziadek, W. Koh, H. Adam, 2020, Scientific Reports.

In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates

D. Hoban, H. Adam, G. Zhanel, 2009, Antimicrobial Agents and Chemotherapy.

Presence of the narrow-spectrum OXA-1 β-lactamase enzyme is associated with elevated piperacillin/tazobactam MIC values among ESBL-producing Escherichia coli clinical isolates (CANWARD, 2007–18)

M. Mulvey, J. Karlowsky, P. Lagacé-Wiens, 2022, JAC-antimicrobial resistance.

Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19

M. Mulvey, Denice C. Bay, J. Karlowsky, 2022, JAC-antimicrobial resistance.

Use of Fosfomycin Etest To Determine In Vitro Susceptibility of Clinical Isolates of Enterobacterales Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci

J. Karlowsky, P. Lagacé-Wiens, H. Adam, 2021, Journal of clinical microbiology.

Susceptibility of Clinical Isolates of Escherichia coli to Fosfomycin as Measured by Four In Vitro Testing Methods

J. Karlowsky, P. Lagacé-Wiens, H. Adam, 2020, Journal of Clinical Microbiology.

In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study

J. Karlowsky, H. Adam, M. Baxter, 2018, Antimicrobial Agents and Chemotherapy.

Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006.

D. Hoban, H. Adam, G. Zhanel, 2009, International journal of antimicrobial agents.

Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study.

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2013, The Journal of antimicrobial chemotherapy.

In Vitro Activity of Ceftaroline against Gram-Positive and Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals in 2009

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2011, Antimicrobial Agents and Chemotherapy.

Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007-16.

W. Demczuk, I. Martin, M. Mulvey, 2019, The Journal of antimicrobial chemotherapy.

Invasive Streptococcus pneumoniae in Canada, 2011-2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F.

H. Adam, G. Zhanel, A. Golden, 2016, Vaccine.

Community-associated methicillin-resistant Staphylococcus aureus: prevalence in skin and soft tissue infections at emergency departments in the Greater Toronto Area and associated risk factors.

V. Allen, R. Goldman, J. Lee, 2009, CJEM.

Bacterial Nomenclature - A Moving Target?

J. Karlowsky, M. Alfa, P. Lagacé-Wiens, 2013 .

Evaluation of the Hologic Aptima Combo 2 Assay for Detection of Neisseria gonorrhoeae from Joint Fluid Specimens

P. V. Van Caeseele, I. Martin, J. Karlowsky, 2022, Journal of clinical microbiology.

Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-15.

M. Gilmour, W. Demczuk, I. Martin, 2018, The Journal of antimicrobial chemotherapy.

Increasing Genetic Relatedness of Ciprofloxacin-Resistant Streptococcus pneumoniae Isolated in Canada from 1997 to 2005

J. Karlowsky, D. Hoban, H. Adam, 2008, Antimicrobial Agents and Chemotherapy.

Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-15.

M. Gilmour, W. Demczuk, I. Martin, 2018, The Journal of antimicrobial chemotherapy.

Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.

M. Mulvey, D. Hoban, V. Loo, 2011, Diagnostic microbiology and infectious disease.

A Review of New Fluoroquinolones

D. Hoban, A. Noreddin, H. Adam, 2006, Treatments in respiratory medicine.

Comparison of PCV-10 and PCV-13 vaccine coverage for invasive pneumococcal isolates obtained across Canadian geographic regions, SAVE 2011 to 2017.

W. Demczuk, I. Martin, M. Mulvey, 2020, Diagnostic microbiology and infectious disease.

An Implementation Strategy for the Use of Chromogenic Media in the Rapid, Presumptive Identification of Candida Species

Y. Yau, H. Adam, S. Richardson, 2010 .

Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2013, Drugs.

Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017.

J. Karlowsky, H. Adam, M. Baxter, 2020, The Journal of antimicrobial chemotherapy.

PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium difficile Surveillance Study (CAN-DIFF) 2013-2015.

J. Karlowsky, H. Adam, M. Baxter, 2018, Diagnostic microbiology and infectious disease.

Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.

M. Mulvey, J. Pitout, J. Karlowsky, 2013, The Journal of antimicrobial chemotherapy.

Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007-13.

M. Gilmour, J. Karlowsky, D. Hoban, 2015, The Journal of antimicrobial chemotherapy.

Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011-13.

M. Gilmour, W. Demczuk, I. Martin, 2015, The Journal of antimicrobial chemotherapy.

Compilation of 10 Years of MIRU-VNTR Data: Canadian National Tuberculosis Laboratory's Experience

G. Tyrrell, D. Haldane, C. Corbett, 2022, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

Evaluation of MRSASelect (™) chromogenic medium for the early detection of methicillin-resistant Staphylococcus aureus from blood cultures.

K. Manickam, J. Karlowsky, M. Alfa, 2013, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

Ceftolozane/Tazobactam: A Novel Cephalosporin/b-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli George G. ZhanelPhillip ChungHeather AdamSheryl ZelenitskyAndrew Denisuik • Frank SchweizerPhilippe R. S. Lagace ´-WiensEthan RubinsteinAlfred S. GinAndrew

D. Hoban, H. Adam, A. Walkty, 2014 .

Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2013, Drugs.

Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-16 study.

M. Mulvey, J. Blondeau, J. Karlowsky, 2019, The Journal of antimicrobial chemotherapy.

Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2016, Drugs.

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019

M. Mulvey, Denice C. Bay, J. Karlowsky, 2022, Microbiology spectrum.

In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008–16

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2018, The Journal of antimicrobial chemotherapy.

Canadian recommendations for laboratory interpretation of multiple or extensive drug resistance in clinical isolates of Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa.

Rafael Cruz Reyes, M. Gilmour, T. Dingle, 2018, Canada communicable disease report = Releve des maladies transmissibles au Canada.

In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.

J. Karlowsky, H. Adam, M. Baxter, 2017, Diagnostic microbiology and infectious disease.

Nontoxigenic Vibrio cholerae Septicemia in an Immunocompromised Patient

M. Gilmour, H. Adam, K. Kadkhoda, 2012, Case reports in infectious diseases.

difficile Infection Laboratory Diagnosis of Clostridium Comparison with the Illumigene Assay for Evaluation of an Algorithmic Approach in

K. Manickam, J. Karlowsky, M. Alfa, 2014 .

Evaluation of an Algorithmic Approach in Comparison with the Illumigene Assay for Laboratory Diagnosis of Clostridium difficile Infection

K. Manickam, J. Karlowsky, M. Alfa, 2013, Journal of Clinical Microbiology.

Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens

M. Gilmour, J. Karlowsky, D. Hoban, 2015, Drugs.

New Lipoglycopeptides

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2010, Drugs.

Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria

Denice C. Bay, J. Karlowsky, K. Naber, 2022, Drugs.

In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli

J. Karlowsky, P. Lagacé-Wiens, H. Adam, 2018, Antimicrobial Agents and Chemotherapy.

Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study.

J. Blondeau, D. Low, J. Karlowsky, 2011, Diagnostic microbiology and infectious disease.

In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.

S. Poutanen, J. Karlowsky, D. Hoban, 2011, Diagnostic microbiology and infectious disease.

In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.

J. Karlowsky, H. Adam, M. Baxter, 2014, Diagnostic microbiology and infectious disease.

Evaluation of three MALDI‐TOF mass spectrometry libraries for the identification of filamentous fungi in three clinical microbiology laboratories in Manitoba, Canada

R. Piarroux, A. Normand, M. Hendrickx, 2018, Mycoses.

Identification of a new species, Candida subhashii, as a cause of peritonitis.

S. Poutanen, M. Groenewald, H. Adam, 2009, Medical mycology.

Pseudo-Outbreak of Phaeoacremonium parasiticum from a Hospital Ice Dispenser

E. Trepman, H. Adam, J. Embil, 2014, Infection Control & Hospital Epidemiology.

Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2017, Drugs.

Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study.

M. Mulvey, J. Pitout, D. Hoban, 2011, Diagnostic microbiology and infectious disease.

Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016.

M. Mulvey, J. Karlowsky, D. Hoban, 2019, The Journal of antimicrobial chemotherapy.

Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007-2009 study.

M. Mulvey, D. Hoban, P. Lagacé-Wiens, 2011, Diagnostic microbiology and infectious disease.

In Vitro Activity of Ceftaroline-Avibactam against Gram-Negative and Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals from 2010 to 2012: Results from the CANWARD Surveillance Study

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2013, Antimicrobial Agents and Chemotherapy.

Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study.

R. Rennie, J. Karlowsky, D. Hoban, 2011, Diagnostic microbiology and infectious disease.

Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2008)

Michael R. Mulvey, M. Mulvey, J. Karlowsky, 2010, Antimicrobial Agents and Chemotherapy.

Mutant Prevention Concentrations of Levofloxacin Alone and in Combination with Azithromycin, Ceftazidime, Colistin (Polymyxin E), Meropenem, Piperacillin-Tazobactam, and Tobramycin against Pseudomonas aeruginosa

H. Adam, G. Zhanel, N. Laing, 2006, Antimicrobial Agents and Chemotherapy.

Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada.

D. Hoban, P. Lagacé-Wiens, H. Adam, 2013, The Journal of antimicrobial chemotherapy.

Frequency of 16S ribosomal RNA methyltransferase detection among Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013-2017).

A. Bharat, M. Mulvey, M. Bergevin, 2019, Diagnostic microbiology and infectious disease.

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli

J. Karlowsky, A. Noreddin, P. Lagacé-Wiens, 2019, Drugs.

In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015.

J. Karlowsky, H. Adam, M. Baxter, 2017, Diagnostic microbiology and infectious disease.

Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia

L. Mandell, Denice C. Bay, J. Karlowsky, 2020, Drugs.

Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent

Denice C. Bay, J. Karlowsky, P. Lagacé-Wiens, 2020, Drugs.

Fosfomycin resistance mediated by fos genes remains rare among extended-spectrum beta-lactamase-producing Escherichia coli clinical isolates recovered from the urine of patients evaluated at Canadian hospitals (CANWARD, 2007-2017).

M. Mulvey, Denice C. Bay, J. Karlowsky, 2019, Diagnostic microbiology and infectious disease.

Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.

D. Hoban, H. Adam, A. Denisuik, 2014, The Journal of antimicrobial chemotherapy.

Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.

M. Gilmour, W. Demczuk, I. Martin, 2012, Canadian journal of microbiology.

Baseline epidemiology of Streptococcus pneumoniae serotypes in Canada prior to the introduction of the 13-valent pneumococcal vaccine.

M. Gilmour, J. Karlowsky, D. Hoban, 2012, Microbial drug resistance.

Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008-2011.

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2012, Diagnostic microbiology and infectious disease.

Comparison of commercial assays and laboratory developed tests for detection of SARS-CoV-2

P. V. Van Caeseele, J. Karlowsky, H. Adam, 2020, Journal of Virological Methods.

42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study.

M. Mulvey, Denice C. Bay, J. Karlowsky, 2019, The Journal of antimicrobial chemotherapy.

positive clinical isolates obtained from patients in Canadian hospitals as

D. Hoban, P. Lagacé-Wiens, H. Adam, 2014 .

Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2007)

Michael R. Mulvey, M. Mulvey, J. Karlowsky, 2009 .

Clinical Metagenomics Is Increasingly Accurate and Affordable to Detect Enteric Bacterial Pathogens in Stool

Eduardo N. Taboada, M. Graham, N. Knox, 2022, Microorganisms.

Cefotaxime susceptibility should not be used to predict ceftriaxone susceptibility among Klebsiella oxytoca clinical isolates.

J. Karlowsky, H. Adam, A. Walkty, 2020, Journal of Global Antimicrobial Resistance.

In Vitro Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals in the CANWARD Study, 2007 to 2012

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2013, Antimicrobial Agents and Chemotherapy.

Invasive pneumococcal disease caused by serotypes 22F and 33F in Canada: the SAVE study 2011-2018.

W. Demczuk, I. Martin, J. Karlowsky, 2021, Diagnostic microbiology and infectious disease.

Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential

I. Martin, M. Mulvey, J. Karlowsky, 2017, The Journal of antimicrobial chemotherapy.

Detection and Characterization of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates in Canada: Results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006

M. Loeb, M. Mulvey, D. Gravel, 2009, Antimicrobial Agents and Chemotherapy.

Species distribution and antifungal susceptibility of invasive Candida isolates from Canadian hospitals: results of the CANWARD 2011-16 study.

T. Dingle, J. Karlowsky, H. Adam, 2019, The Journal of antimicrobial chemotherapy.

Molecular characterization of predominant Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011-15.

M. Gilmour, P. V. Van Caeseele, W. Demczuk, 2018, The Journal of antimicrobial chemotherapy.

Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008.

J. Karlowsky, D. Hoban, H. Adam, 2014, The Journal of antimicrobial chemotherapy.

Pertussis Testing: Pathogen and Laboratory Identification

P. Lagacé-Wiens, H. Adam, K. Nichol, 2015 .

Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals.

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2013, The Journal of antimicrobial chemotherapy.

In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.

J. Karlowsky, D. Hoban, H. Adam, 2011, Diagnostic microbiology and infectious disease.

Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study

M. Mulvey, J. Karlowsky, D. Hoban, 2018, The Journal of antimicrobial chemotherapy.

Ten years of the CANWARD Study (2007-16).

H. Adam, G. Zhanel, 2019, The Journal of antimicrobial chemotherapy.

Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada--results of the CANWARD 2007-2009 study.

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2011, Diagnostic microbiology and infectious disease.

In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2014, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.

J. Karlowsky, P. Lagacé-Wiens, H. Adam, 2020, Diagnostic microbiology and infectious disease.

Identification of Blood Culture Isolates Directly from Positive Blood Cultures by Use of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry and a Commercial Extraction System: Analysis of Performance, Cost, and Turnaround Time

J. Karlowsky, M. Alfa, P. Lagacé-Wiens, 2012, Journal of Clinical Microbiology.

Re-evaluation of rejection criteria for endotracheal tube (ETT) specimens from adult patients.

K. Manickam, J. Karlowsky, M. Alfa, 2012, Journal of medical microbiology.

CHROMagar Orientation Medium Reduces Urine Culture Workload

K. Manickam, J. Karlowsky, M. Alfa, 2013, Journal of Clinical Microbiology.

2 ) 1 2 3 CHROMagar TM Orientation Media Reduces Urine Culture Workload 4 5

K. Manickam, J. Karlowsky, M. Alfa, 2013 .

Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007-2018.

W. Demczuk, I. Martin, M. Mulvey, 2021, Vaccine.

In vitro activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD 2007-18).

J. Karlowsky, P. Lagacé-Wiens, H. Adam, 2021, The Journal of antimicrobial chemotherapy.

Antimicrobial susceptibility of 2906 Pseudomonasaeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015.

M. Mulvey, J. Karlowsky, P. Lagacé-Wiens, 2017, Diagnostic microbiology and infectious disease.

Streptococcus pneumoniae serotyping and antimicrobial susceptibility: assessment for vaccine efficacy in Canada after the introduction of PCV13.

H. Adam, G. Zhanel, J. P. Lynch, 2023, The Journal of antimicrobial chemotherapy.

In Vitro Activity of Fosfomycin against Escherichia coli Isolated from Patients with Urinary Tract Infections in Canada as Part of the CANWARD Surveillance Study

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2013, Antimicrobial Agents and Chemotherapy.

Fatal case of post-influenza, community-associated MRSA pneumonia in an Ontario teenager with subsequent familial transmission.

H. Adam, A. Simor, A. McGeer, 2007, Canada communicable disease report = Releve des maladies transmissibles au Canada.

Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model.

J. Pitout, J. Karlowsky, A. Noreddin, 2017, Diagnostic microbiology and infectious disease.

In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016.

J. Karlowsky, P. Lagacé-Wiens, H. Adam, 2019, International Journal of Antimicrobial Agents.

Epidemiology of Vancomycin-Resistant Enterococci in Canadian Hospitals (CANWARD Study, 2007 to 2013)

M. Gilmour, J. Karlowsky, D. Hoban, 2015, Antimicrobial Agents and Chemotherapy.

In vitro activity of sulopenem against 1880 bacterial pathogens isolated from Canadian patients with urinary tract infections (CANWARD, 2014-21).

J. Karlowsky, P. Lagacé-Wiens, H. Adam, 2022, Journal of Antimicrobial Chemotherapy.

Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007-16.

M. Mulvey, S. Poutanen, J. Karlowsky, 2019, The Journal of antimicrobial chemotherapy.

Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015).

M. Mulvey, S. Poutanen, J. Karlowsky, 2016, CMAJ open.

Prevalence of Antimicrobial Resistance among Clinical Isolates of Bacteroides fragilis Group in Canada in 2010-2011: CANWARD Surveillance Study

J. Karlowsky, D. Hoban, H. Adam, 2011, Antimicrobial Agents and Chemotherapy.

In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to lefamulin, a new pleuromutilin.

J. Karlowsky, P. Lagacé-Wiens, H. Adam, 2021, Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada.

Molecular Characterization of Increasing Fluoroquinolone Resistance in Streptococcus pneumoniae Isolates in Canada, 1997 to 2005

C. Hoban, D. Hoban, H. Adam, 2006, Antimicrobial Agents and Chemotherapy.

Antimicrobial resistance patterns of bacterial pathogens recovered from the urine of patients at Canadian hospitals from 2009 to 2020

J. Karlowsky, P. Lagacé-Wiens, H. Adam, 2022, JAC-antimicrobial resistance.

Genomic investigation of the most common Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011-2020.

P. V. Van Caeseele, W. Demczuk, I. Martin, 2023, The Journal of antimicrobial chemotherapy.

Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-2020.

W. Demczuk, I. Martin, M. Mulvey, 2023, The Journal of antimicrobial chemotherapy.

Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive Streptococcus pneumoniae isolate serotypes in Canada: the SAVE study, 2011-20.

W. Demczuk, I. Martin, M. Mulvey, 2023, The Journal of antimicrobial chemotherapy.

Characterization of MRSA in Canada from 2007 to 2016.

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2019, The Journal of antimicrobial chemotherapy.

Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model.

J. Karlowsky, D. Hoban, A. Noreddin, 2012, The Journal of antimicrobial chemotherapy.

Genotypic characterization of tuberculosis transmission within Toronto's under-housed population, 1997-2008.

E. Rea, H. Adam, S. Bolotin, 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-2020.

W. Demczuk, I. Martin, M. Mulvey, 2023, Journal of Antimicrobial Chemotherapy.

Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.

C. Hoban, D. Hoban, H. Adam, 2005, Journal of Antimicrobial Chemotherapy.

Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae.

D. Hoban, H. Adam, G. Zhanel, 2006, International journal of antimicrobial agents.

Short communication Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae

D. Hoban, H. Adam, G. Zhanel, 2006 .

In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019.

J. Karlowsky, P. Lagacé-Wiens, H. Adam, 2021, Diagnostic microbiology and infectious disease.

Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011-13.

M. Gilmour, W. Demczuk, I. Martin, 2015, The Journal of antimicrobial chemotherapy.

Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals.

J. Karlowsky, D. Hoban, P. Lagacé-Wiens, 2013, The Journal of antimicrobial chemotherapy.